Biotech funding is available - for companies with a clear plan
This article was originally published in Scrip
2009 may have been a lean year for biotech firms, but things seem to be looking up and some small companies may well fare better financially this year than their pharma peers, provided they have a good product, a strong business plan and a clear exit strategy.
You may also be interested in...ï»¿
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Life science companies will be pleased to hear that the European Parliament is pressing for close cooperation between the UK and the EU in the area of medicines regulation.